Advertisements

Тазепам

Quick links to important sections

Тазепам

Advertisements
Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Тазепам

Quick Facts: Тазепам

Property Description
Active ingredient Oxazepam (INN)
Form Tablets (film-coated) or Capsules
Pharmacological class Benzodiazepine derivative, Anxiolytic
Common use Relief of excessive tension and anxiety symptoms
Origin Synthetic

Тазепам: Definition, Active Ingredient, and Origin

Тазепам is the trade name for a synthetic, prescription-only medicinal product administered orally, containing the single active ingredient, Oxazepam. This compound is the internationally recognized non-proprietary name (INN) and is classified as an intermediate-acting agent within its chemical class. Pharmacological studies confirm that Oxazepam is structurally distinct as a hydroxylated metabolite, influencing its subsequent processing in the body. This single-agent medication is prepared for patients primarily in the form of film-coated tablets or capsules. The synthetic origin ensures consistency and high purity of the active compound, a characteristic essential for reliably achieving the intended effects.

Pharmacological Classification and Type of Тазепам

The medication is firmly placed within the pharmacological group of benzodiazepine derivatives and is categorized as a psycholeptic agent. Oxazepam is specifically classified as an anxiolytic (anxiety-reducing) agent, a function clinically recognized for its reliable action in reducing excessive agitation and nervousness. Unlike some very short-acting members of the class, Oxazepam is characterized as an intermediate-acting compound. This profile is often favored for managing persistent tension states rather than acute, transient events, distinguishing it from ultra-short-acting analogues.

General Purpose: Why is Тазепам Used?

The overarching purpose of Тазепам is to act as a Central Nervous System (CNS) depressant, which works to quiet and moderate neuronal hyperactivity in the brain. The drug achieves this by enhancing the action of the brain's main inhibitory chemical, GABA. This specific mechanism delivers an anxiolytic effect, alongside secondary sedative and mild muscle relaxant properties. The overall benefit is the systematic reduction of excessive physical and emotional arousal, providing a foundation for stability during periods of heightened tension.

Regulatory References

  1. Oxazepam - StatPearls - NCBI Bookshelf
  2. Oxazepam: MedlinePlus Drug Information
Advertisements

What side effects are possible with Тазепам?

Possible side effects and safety information

The safety profile for Тазепам (Oxazepam) is defined by its classification as a central nervous system (CNS) depressant, with officially documented adverse reactions primarily grouped into neurological and psychiatric domains. These classifications are used by regulatory bodies to communicate the established risks of the medicine.

Adverse Reaction Classification

The most frequently observed adverse reactions are classified as Common and are related to CNS depression, including drowsiness, sedation, ataxia, dizziness, and fatigue. Less frequent, or Uncommon, reactions may include gastrointestinal disturbances or minor skin reactions. Rarer, but clinically significant effects, known as Rare reactions, include paradoxical reactions such as agitation or excitation.

Classification Examples of Reactions
Common Drowsiness, Sedation, Ataxia, Fatigue
Rare Paradoxical reactions (e.g., aggression, excitation)

Serious Safety Considerations

Official labeling recognizes the potential for serious adverse reactions. These include the risk of severe CNS depression, which can lead to respiratory compromise, particularly when the medicine is combined with other CNS depressants, such as alcohol or opioids. The development of physical and psychological dependence is a recognized risk, especially with increased dosage or prolonged use. Abrupt cessation after long-term exposure may result in a defined withdrawal syndrome.

Population-Specific Notes

Safety constraints require particular attention for certain patient populations. Older adults may have heightened sensitivity to the CNS-depressant effects, increasing the risk of falls and injury. The medicine is formally contraindicated by official labeling in patients with pre-existing conditions such as severe hepatic impairment or severe respiratory insufficiency.

Advertisements

Overdose and Emergency Response

Тазепам Overdose and When to Seek Help: Official Regulatory Information

Overdose with Тазепам (Oxazepam) primarily presents as an escalation of its central nervous system (CNS) depressant effects. All official overdose information is derived exclusively from government regulatory prescribing documents.

Domain Officially Documented Overdose Signs and Actions
Documented Manifestations Symptoms range from drowsiness, somnolence, ataxia, and confusion to profound lethargy and dysarthria.
Life-Threatening Outcomes The most serious outcomes documented include respiratory depression, potentially leading to coma and areflexia, and significant hypotension.
Mandated Emergency Action Immediate medical attention must be sought for suspected overdose. Contacting emergency services is required if severe or life-threatening symptoms are present.
Population Notes Increased severity of overdose manifestations is documented in the elderly and in patients with hepatic impairment.
Classification Regulatory Management Context
Severity Classification Overdose is typically benign when taken alone, but is classified as life-threatening in mixed ingestion scenarios.
Management Focus Requires symptomatic and supportive treatment and continuous observation of vital signs. The specific antagonist Flumazenil is noted for use in overdose management.

The official regulatory profile emphasizes that while the standard management involves supportive care and continuous observation, the potential for progression to respiratory depression and coma dictates the necessity for immediate emergency medical intervention. All required procedures, including ventilation maintenance and monitoring, must be performed by qualified medical personnel in a hospital setting.

Advertisements

Therapeutic Uses of Тазепам

Quick Facts

  • Indicated for the short-term management of anxiety disorders.
  • Used to assist in managing symptoms of acute alcohol withdrawal syndrome.

Тазепам (Oxazepam) is a therapeutic option indicated for the management of specific conditions affecting the central nervous system. The medication is utilized primarily in the short-term treatment of anxiety disorders, providing temporary assistance in reducing symptoms such as tension and agitation.

It may also be administered to help patients manage symptoms associated with acute alcohol withdrawal syndrome, including tremor and related states of agitation. Тазепам is part of a comprehensive treatment plan intended to support individuals during episodes of anxiety or withdrawal. This class of medication is intended to offer symptomatic relief and should be used under the direction of a qualified healthcare professional.

Regulatory References

  1. NIH-published therapeutic indications
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Тазепам (Oxazepam) is approved for use in adults and for specific anxiety management in pediatric patients aged 6 to 12 years. However, eligibility is strictly defined and restricted by official regulatory labeling, including absolute contraindications and conditional use rules.

Classification Status Affected Population or Condition
Contraindicated Patients with known hypersensitivity to oxazepam or other benzodiazepines.
Contraindicated Patients with psychoses, myasthenia gravis, or severe respiratory depression.
Not Established Pediatric patients under 6 years of age (safety and effectiveness are not established).
Not Recommended Pregnant women (especially during the first trimester) and breastfeeding women (due to excretion into breast milk).
Conditional Use Older adults (geriatric) due to greater risk of sensitivity, and patients with a history of drug or alcohol dependence (requires careful surveillance).
Conditional Use Patients with hepatic or renal impairment, or those with conditions where a drop in blood pressure could be medically critical.

Eligibility is also restricted by duration; the efficacy of use longer than four months has not been systematically evaluated by regulatory authorities.

Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Тазепам (Oxazepam) is defined primarily by its pharmacodynamic effects on the Central Nervous System (CNS) and its specific metabolic pathway.

Pharmacodynamic Interactions

Co-administration with other substances that cause CNS depression is a key interaction domain, resulting in an additive effect. This includes:

  • Opioid Analgesics: Regulatory documents carry a Boxed Warning regarding the co-use of oxazepam with opioids due to the severe, life-threatening risk of profound sedation, respiratory depression, coma, and death.
  • Alcohol: Use with alcohol is strongly advised against, as it significantly enhances CNS depressant effects.
  • Other CNS Depressants: This includes medications such as Antipsychotics, Sedatives/Hypnotics, Anticonvulsants, and certain Antihistamines, all of which may increase the risk of enhanced sedation.

Pharmacokinetic Interactions

Oxazepam's metabolism occurs through glucuronide conjugation to inactive metabolites, meaning it avoids many common CYP-enzyme interactions. However, its exposure may be modified by other agents:

  • UGT Modifiers: Substances that affect the UGT (Uridine Diphosphate Glucuronosyltransferase) enzymes, such as certain UGT inducers, may potentially decrease the efficacy of oxazepam by speeding up its clearance. Probenecid, an inhibitor of glucuronide clearance, may increase the effects of the drug.
  • Oral Contraceptives: The professional monograph notes that oral contraceptives may cause an apparent increase in oxazepam metabolism, though this is not typically established as a major clinical restriction.

Population-Specific Notes

Elderly and debilitated patients are officially noted to be more susceptible to the additive effects arising from pharmacodynamic interactions with other CNS depressants.

Advertisements

Mechanism of Action

How Тазепам Works

Тазепам (Oxazepam) acts as a central nervous system depressant. Its primary mechanism involves specific modulation of the GABAA receptor complex, leading to an increase in inhibitory signaling within the brain. This action influences resultant physiological effects via altered neural signaling.


GABAA Receptor Positive Allosteric Modulation

Тазепам functions as a positive allosteric modulator (PAM), binding to a distinct site on the receptor (the benzodiazepine site) to enhance the affinity of the inhibitory neurotransmitter GABA. This modulation increases the frequency of chloride ion ( Cl^-) channel opening, hyperpolarizing the neuron.


Modulation of High-Frequency Neural Activity

The increased chloride ion influx suppresses excitability by stabilizing the neuron at a more negative resting potential. This modification promotes the dominance of inhibitory pathways in the central nervous system. The consequence is a reduction in the transmission of nerve impulses, reducing signal transduction efficiency in circuits associated with general excitation, and leading to a reduction in overall neural excitability within the targeted pathways.

Advertisements

Dosage and Administration Information

Official Administration and Dosing Principles

Тазепам (Oxazepam) is administered via the oral route and is available in capsule or tablet strengths, commonly including 10 mg, 15 mg, and 30 mg. The fundamental principle guiding its use is to employ the lowest effective dosage for the shortest possible duration. The medication can be taken with or without food.

Labeled Dosing and Frequency

For the management of mild-to-moderate anxiety, the standard adult dosing regimen is typically 10 mg to 15 mg per dose, while more severe agitation or symptoms associated with alcohol withdrawal utilize a higher range of 15 mg to 30 mg per dose. In all these cases, the dose is generally scheduled to be taken in divided amounts, three or four times daily.

Indication Usual Adult Dose Range (Per Dose) Typical Frequency
Anxiety (Mild-to-Moderate) 10 mg to 15 mg 3 or 4 times daily
Severe Anxiety / Alcohol Withdrawal 15 mg to 30 mg 3 or 4 times daily

Use Duration and Population Guidelines

Treatment with Oxazepam is reserved for short-term use, with the overall duration generally not exceeding four weeks. If a dose is missed, standard practice is to skip the missed dose and return to the regular schedule without doubling the next dose. For older adults, it is common practice to initiate treatment at a lower dose, such as 10 mg taken two or three times daily, before considering any cautious increase. Upon discontinuation, clinical protocols involve a gradual tapering of the dosage to allow the body to adjust.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Тазепам (Oxazepam)

This section provides an overview of the clinical research and evidence base for Oxazepam, focusing exclusively on the types of studies conducted, what outcomes researchers have measured, and what remains uncertain according to authoritative sources.


Evidence for Use in Short-term Management of Anxiety Disorders

Research into Oxazepam was studied for use in individuals with symptoms of anxiety and primarily involved short-term Randomized Controlled Trials (RCTs). These studies were designed to track and measure changes in symptoms such as excessive tension, agitation, and overall anxiety levels in adult patients. Findings describe patterns observed in the studies related to changes measured in tension and agitation during the short-term use period.

It is important to understand that the research mostly focuses on temporary use. Long-term effects are not fully established through systematic evaluation in clinical trials for use beyond approximately four months. Data for certain groups remain insufficient, and existing studies provide limited insight into the durability of any observed changes.


Evidence for Use in Acute Alcohol Withdrawal Syndrome

Oxazepam was studied in research scenarios related to acute symptoms of alcohol withdrawal syndrome (AWS). Research in this area relies on Randomized Controlled Trials (RCTs) and analyses that often compared Oxazepam to other agents or to a placebo. Studies were conducted during periods of increased symptom activity, focusing on outcomes related to episodic or acute changes.

Findings describe patterns observed in the studies related to the rate at which acute withdrawal symptoms were tracked. The evidence base, often grouped with data from similar medicines, contributes to the broader evidence landscape for understanding symptom patterns associated with acute or disruptive episodes. The majority of this evidence is limited to studies observing responses during the acute phase, typically lasting no more than ten days.


Key Limitations and Areas of Research Uncertainty

The current research highlights key limitations in the evidence base for Oxazepam. The follow-up durations were limited across many anxiety trials, which makes it challenging to draw conclusions about use beyond the short term. The evidence for continuous, long-term use is not fully established, meaning that certainty remains low. Furthermore, while Oxazepam was studied for specific indications, the evidence quality varies across studies, and the data for long-term neurocognitive or functional outcomes remain uncertain.

Key Studies & References

  1. Label: OXAZEPAM capsule, gelatin coated - DailyMed
  2. Benzodiazepines in Older Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines - NCBI
  3. A 5-year follow-up study of users of benzodiazepine: starting with diazepam versus oxazepam
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Тазепам (FAQ)

Q: How quickly does Тазепам start working for symptoms like anxiety or muscle spasms?

According to the official product information, peak plasma levels of Тазепам, which represent the highest concentration of the drug in the bloodstream, are generally observed about 3 hours after dosing. This time frame suggests how quickly the drug may reach its maximum concentration in the body.


Q: How long does the effect of a single dose of Тазепам typically last?

Regulatory information indicates that the mean elimination half-life of Тазепам (Oxazepam) is approximately 8.2 hours, with a reported range of 5.7 to 10.9 hours. The half-life is the time it takes for half of the drug to be eliminated from the body. Because it has an intermediate half-life, it is often utilized for persistent tension states.


Q: What are the common symptoms of Тазепам withdrawal?

Official warnings note that stopping the medication abruptly after using it for a while may result in a defined withdrawal syndrome. Symptoms reported in regulatory documents include convulsions, tremor, muscle cramps, vomiting, and sweating. Milder symptoms such as feeling generally unwell (dysphoria) and insomnia have also been reported.


Q: Can taking Тазепам cause changes in mood or make depression worse?

The medication's official indications include anxiety associated with depression. However, official information notes that the drug's use is subject to special considerations for patients with a history of depression. Regulatory documents also note that rare, sometimes called paradoxical reactions, such as excitement or stimulation of affect, may occur.


Q: Can Тазепам be used to help with sleep or insomnia?

The medication is indicated for the management of anxiety disorders and for acute alcohol withdrawal symptoms. While the drug has recognized sedative properties, official labeling lists its approved uses as anxiety management and acute alcohol withdrawal, not chronic insomnia.


Q: What are the signs of a possible allergic reaction to Тазепам that require immediate attention?

Regulatory documents state that Тазепам is contraindicated if a person has a known history of hypersensitivity to the active ingredient or other similar medicines. Serious reactions that require immediate medical attention may include severe skin rash or developing difficulty breathing/swallowing.


Q: What is the potential risk of developing memory problems while on Тазепам?

Official documentation lists side effects of unknown frequency, such as being forgetful, confusion, or problems with memory. Patients should be aware that these potential cognitive effects have been reported.


Q: Are there any specific lifestyle changes recommended when taking Тазепам (e.g., diet, activity)?

Regulatory warnings state that individuals using the medication should avoid driving or operating dangerous machinery until they are certain how the therapy affects them. This caution is due to the potential for common side effects like drowsiness or dizziness.


Q: What are the legal classification and control status of Тазепам?

According to official government regulation, Тазепам (Oxazepam) is classified as a federal controlled substance and is designated as a Schedule IV drug. This classification indicates that the drug has a recognized medical use but carries a potential for abuse or dependence.


Q: Does the body build tolerance to the effects of Тазепам over time?

The official warnings state that the risks of dependence and withdrawal reactions are known to increase with longer treatment duration and higher daily dose. Therefore, the medication is approved only for short-term use.


Q: Can Тазепам be used as an add-on treatment for certain seizure disorders?

Official labeling does not list seizure disorders as a human indication for Тазепам. While some animal studies indicate the drug exerts an anticonvulsant activity, its approved use remains limited to anxiety management and acute alcohol withdrawal.


Q: Does Тазепам have an impact on a person's ability to drive or operate machinery?

Regulatory warnings note that individuals should avoid driving automobiles or operating dangerous machinery until its effects (like drowsiness or dizziness) are known. This is a standard precaution due to the drug's properties as a central nervous system depressant.


Q: Are there specific symptoms that indicate a high level of Тазепам in the body?

Symptoms of a potential overdose or high systemic levels, as listed in the official documents, include blurred vision, change in consciousness, confusion, or loss of consciousness. Other signs are muscle pain or weakness and extreme drowsiness.


Q: What is the difference between physical dependence and addiction regarding Тазепам?

Official warnings discuss the risks of abuse, misuse, addiction, and physical/psychological dependence associated with Тазепам use. The label acknowledges these as distinct but related safety considerations and advises following treatment protocols precisely.


Q: Can Тазепам cause strange or vivid dreams?

Official drug safety information lists nightmares among the possible adverse reactions. However, the exact frequency of this specific side effect is not clearly established by regulatory data.


Q: Is it normal to have a dry mouth or change in appetite while taking Тазепам?

Regulatory safety data notes that dry mouth and loss of appetite are listed as possible side effects that have been reported. The incidence of these specific reactions in the overall patient population is not known.


Q: Are there different brand names or generic versions of Тазепам?

Yes, the active ingredient in Тазепам is Oxazepam. Official government labeling refers to both the brand name (such as Serax) and its generic form, indicating that both brand and generic versions of the medication exist and are available.

Advertisements

How should Тазепам be stored and disposed of?

Storage Requirements

Storage Condition Regulatory Requirement
Temperature Range Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Environmental Protection Keep out of the light and away from excessive heat and moisture; do not freeze.
Container Rules Must be stored in the closed, original container and kept tightly closed.
Child Safety Keep out of the reach and sight of children and pets. Store in a secure location to prevent misuse.

Disposal Instructions

Unused or expired Тазепам (Oxazepam) must be disposed of safely due to its classification as a controlled substance. The preferred method is to return the medication to a drug take-back program or authorized disposal location. If a take-back option is unavailable, the product must be mixed with an unappealing substance (like dirt or coffee grounds) in a sealed bag and thrown in the trash, following regulatory guidelines for household disposal. The medication must not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Тазепам found in:

A-Z Index: